Cover Image

SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR

Idiopathic thrombocytopenic purpura is a chronic autoimmune hematological disease caused by an increased destruction of platelets and associated thrombocytopenia, for the treatment of which the imported drug romiplostim is used. Сreation of the drug biosimilar provides a reduction in the cost of the...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. N. Afanasyeva (Author), V. B. Saparova (Author), D. D. Karal-Ogly (Author), E. I. Mukhametzyanova (Author), D. V. Kurkin (Author), A. V. Kalatanova (Author), I. E. Makarenko (Author), A. L. Khokhlov (Author), I. A. Lugovik (Author)
Format:	Book
Published:	Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute, 2022-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A randomized, double‐blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers
by: Igor Makarenko, et al.
Published: (2023)

Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use
by: D. V. Kurkin, et al.
Published: (2023)

Biosimilars - drugs of the future
by: E. A. Eltcova, et al.
Published: (2014)

Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy
by: Buchbinder D, et al.
Published: (2017)

Generics and biosimilars in oncology
by: I. A. Gopienko, et al.
Published: (2020)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024)

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
by: Tremblay G, et al.
Published: (2018)

Guidelines of research biosimilar drugs
by: R. . Ivanov, et al.
Published: (2014)

An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world data
by: D. P. Kamilova, et al.
Published: (2021)

Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers
by: Sara Moufarrij, et al.
Published: (2024)

Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
by: Tremblay G, et al.
Published: (2018)

Biosimilar insulins in international and domestic practice of pharmacist
by: I. O. Vlasenko, et al.
Published: (2022)

The Efficacy and Safety of Biosimilars in Hidradenitis Suppurativa: A Comprehensive Review
by: Almukhadeb E, et al.
Published: (2024)

Aplastic anemia with thrombopoietin gene mutation successfully treated with romiplostim monotherapy
by: Niranjan Gurunath Hegde, et al.
Published: (2023)

Efficacy of Russian insulin biosimilars for type 1 diabetes in adolescents
by: V.V. Platonov, et al.
Published: (2022)

THE NOVEL BIOSIMILAR OF FOLLITROPIN ALPHA TO BE MANUFACTURED IN RUSSIA STARTING FROM 2017
by: I. I. Vorobiev, et al.
Published: (2017)

Romiplostim - an emergency treatment of intracranial haemorrhage in the course of severe primary immune thrombocytopaenia
by: Paweł Łaguna, et al.
Published: (2022)

INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW
by: D. G. Tolkacheva, et al.
Published: (2018)

INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW
by: D. G. Tolkacheva, et al.
Published: (2018)

Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available
by: F. V. Gorkavenko, et al.
Published: (2019)

Safety of Use of Russian Biosimilars of Interferon Beta-1b in the Treatment of Multiple Sclerosis: a Meta-analysis of Original Studies
by: D. O. Gudz, et al.
Published: (2019)

ECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSES
by: V. S. Krysanova, et al.
Published: (2021)

DETERMINATION OF ANTIMICROBIAL ACTIVITY OF EXTRACTS OF CALENDULA OFFICINALIS FLOWERS
by: P. V. Afanasyeva, et al.
Published: (2016)

Major results of a phase III comparative multicenter study on the follitropin alfa biosimilar (Primapur®) and the original follitropin alfa (Gonal-f®)
by: Z. B. Barakhoeva, et al.
Published: (2018)

Bioequivalence study of fixed-dose combination Losartan + amlodipine + rosuvastatin Sanofi in comparison with coadministered fixed- dose combination Lozap® AM and monocomponent drug Crestor® in healthy subjects
by: A. L. Khokhlov, et al.
Published: (2022)

FEATURES OF QUANTITATIVE ESTIMATION OF FLAVONOID CONTENT IN JUGLANS NIGRA L. BARKS PREPARATIONS
by: V. A. Kurkin, et al.
Published: (2022)

SAFETY AND CLINICAL EFFICACY IN BIOSIMILAR SUBSTITUTION
by: João Pedro Fernandes, et al.
Published: (2015)

SAFETY AND CLINICAL EFFICACY IN BIOSIMILAR SUBSTITUTION
by: João Pedro Fernandes, et al.
Published: (2015)

Methodological and regulatory aspects of pharmaceutical development of biological products
by: D. V. Kurkin, et al.
Published: (2024)

Optimization of therapeutic drug monitoring of vancomycin in newborns using "Dried Blood Spot" method
by: V. I. Petrov, et al.
Published: (2024)

Missing Cells - A Rare Case of Persisting Thrombocytopenia in Pregnancy With Dengue and Role of Romiplostim in These Cases
by: Ruchita Sinha, et al.
Published: (2023)

ACUTE STENOSING LARYNGOTRACHEITIS IN RESPIRATORY VIRAL INFECTIONS IN CHILDREN IN THE CLINICS OF ST. PETERSBURG
by: V. F. Sukhovetskaya, et al.
Published: (2017)

ACTIVITY MODULATION OF VARIOUS NITRIC OXIDE SYNTASES AS AN APPROACH TO ENDOTHELIAL DYSFUNCTION THERAPY
by: D. V. Kurkin, et al.
Published: (2022)

Investigating the current state of the Russian market for drugs treating infectious and inflammatory conditions of oral cavity and oropharynx to demonstrate the need for new drug development
by: V. I. Zvereva, et al.
Published: (2024)

Correction of psychological and neurological signs of alcohol hangover in rats with acetylcysteine
by: D. V. Kurkin, et al.
Published: (2019)

Overview of drugs approved by the FDA in 2022
by: D. V. Kurkin, et al.
Published: (2023)

A review of biosimilars in psoriasis: impacts on efficacy, safety, access, and a first-hand look at biosimilar cost savings within the department of veterans affairs
by: Rebecca Reese, et al.
Published: (2024)

The use of a new oral antiviral drug molnupiravir in the treatment of COVID-19 from a safety perspective
by: A. L. Khokhlov, et al.
Published: (2022)

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)
by: M. Yu. Fedyanin, et al.
Published: (2023)

Romiplostim-associated increase in CD34+ megakaryocytes in a case of immune thrombocytopenia: A case report
by: Charles M. Lombard, et al.
Published: (2023)